DRG Market Assessment reports

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives…

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease…

No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs)…

Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…

For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil,…

The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving ample room for novel, more-effective alternatives…

For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine…

Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat…

The market for Alzheimer’s disease (AD) pharmacotherapies represents an enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is…

There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation affects the majority of diagnosed AD patients,…

For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive symptomatic therapies (e.g., donepezil, memantine)…

Although the Alzheimer’s disease (AD) treatment paradigm is stable and most current treatments in the United States are generically available, several new therapies for AD, including the first…